Skip to main content
padlock icon - secure page this page is secure

Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody

Buy Article:

$52.00 + tax (Refund Policy)

We describe a patient with systemic lupus erythematosus (SLE) associated with topoisomerase I (topo I, Scl-70) antibody, a specific marker for systemic sclerosis (SSc). SSc patients who produce this antibody have severe cutaneous and visceral involvement, and eventually have a poor prognosis. It is rare to find this antibody in patients with other collagen diseases. Only four SLE patients have been reported in the English language literature who were topo I antibody-positive but had no clinical evidence of scleroderma. The serum of our patient with SLE had precipitating topo I antibody from the onset of his disease. Twelve years after the onset of SLE, he developed proximal scleroderma and pulmonary fibrosis. This case reconfirms the prognostic significance of topo I antibody as a predictive marker, and indicates that SLE patients with topo I antibody require careful follow-up for future development of scleroderma.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Scl-70 antibody; systemic lupus erythematosus; systemic sclerosis; topoisomerase I antibody

Document Type: Research Article

Affiliations: Department of Dermatology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan

Publication date: May 1, 2000

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more